Abstract
PI3Kδ has a central role in the BCR signaling in hematological malignancies. Idelalisib was the first-in-class PI3Kδ inhibitor, and several novel compounds are undergoing clinical investigation. To identify modalities to overcome the resistance developed to these agents, we have developed idelalisib-resistant models derived from MZL cell lines.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
